A Phase I Study of ORIC-944 to Treat Metastatic Prostate Cancer

Full Title

An Open-Label, Phase 1/1b, Study of ORIC-944 as a Single Agent or in Combination with an Androgen Receptor Pathway Inhibitor in Patients with Metastatic Prostate Cancer

Purpose

In this study, researchers want to find the highest dose of the investigational drug ORIC-944 that can be given safely in people with metastatic prostate cancer that continues to grow despite standard treatments. ORIC-944 works by blocking a group of proteins called PRC2, which promote prostate cancer growth. It is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

• Participants must have metastatic prostate cancer that continues to grow despite standard treatments.
• At least 3 weeks must pass since the completion of prior anticancer medications and 2 weeks since radiation therapy and receipt of ORIC-944.
• Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
• This study is for people age 18 and older.

Contact

For more information and to ask about eligibility for this study, please contact the office of Dr. Wassim Abida at 646-422-4633.